Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry. // European Urology Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S258893112600180X?dgcid=rss_sd_all
Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry. European Urology Oncology. https://www.sciencedirect.com/science/article/pii/S258893112600180X?dgcid=rss_sd_all
“Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry.” European Urology Oncology.
@article{article107487,
title = {Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry},
journal = {European Urology Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S258893112600180X?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...